Phase 4
Completed N=82
Seizure Prophylaxis in Aneurysm Repair
Source: ClinicalTrials.gov NCT01801072 ↗Enrolled (actual)
82
Serious AEs
4.9%
Results posted
Nov 2024
Primary outcomePrimary: Incidence of Seizure — 2; 1; 0; 0 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
After a thorough review of the existing literature as well as a review of our own practice, the investigators have concluded that the decision to treat patients undergoing aneurysm repair with levetiracetam has reached true clinical equipoise. In other words, the investigators cannot favor a decision to either administer or not administer this drug in these patients based on the existing information. The utility of anti-epileptic prophlaxis in the perioperative period for patients undergoing intracranial aneurysm repair remains a common practice that is not supported by the current literature that includes retrospective analyses as well as prospective trials for similar but not identical types of patients. The investigators propose to settle this dilemma by performing a prospective randomized trial in patients undergoing aneurysm repair in order to definitively determine if the common practice of perioperative antiepileptic drug administration has any utility. The study will be extended to June 2024 to allow for a 5 year follow up of the last enrolled patient in June, 2019.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Seizure |
2; 1; 0; 0; 0; 0 | — |
| SECONDARY Duration of Seizure |
— | — |
Eligibility Criteria
Inclusion Criteria
- Adult (≥18 years)
- Presence of intracranial aneurysm (with or without rupture)
- Treating surgeon has recommended surgical repair of the aneurysm
Exclusion Criteria
- History of seizures within last 10 years
- History of epilepsy
- History of prior stroke
- Currently prescribed medication with anti-epileptic activity (keppra, dilantin, tegretol, lamictal, topamax, etc.)
- Brain tumor
- Pregnant or nursing woman
- Known levetiracetam allergy
Data sourced from ClinicalTrials.gov (NCT01801072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.